Acute ischemic stroke is also referred to as brain ischemia and cerebral ischemia. This stroke is caused when a blockage occurs in an artery supplying blood to the brain. The blockage reduces blood flow and oxygen to the brain, causing brain cells to be damaged or killed. If circulation is not quickly restored, brain damage can be permanent. This blockage can emerge at the neck or in the skull and is also called as clot or plaque. The optimum treatment for ischemic stroke include tissue plasminogen activator (tPA), which is an intravenous medicine that can dissolve the stroke-causing clot and is usually administered through a vein in the arm within the first three hours of the stroke.
Clots can be removed surgically, if tissue plasminogen activator (tPA) is not able to remove the blood clots from the brain. After the onset of stroke symptoms, mechanical thrombectomy, an intervention procedure can be performed to remove blood clots within 24 hours of the stroke. To prevent further clots, long-term treatments may include aspirin (Bayer) or an anticoagulant.
If one’s ischemic stroke is caused by a condition such as high blood pressure or atherosclerosis, they would need to be treated for that too. For instance, the doctor may suggest a stent to open a plaque-clogged artery or statins to lower blood pressure.
Global Acute Ischemic Stroke Therapeutics Market – Dynamics
Rising cases of ischemic stroke is expected to propel growth of the global acute ischemic stroke therapeutics market. For instance, according to the U.S. Centers for Disease Control and Prevention (CDC), in 2018, over 795,000 people in the U.S. suffered from a stroke. Around 610,000 people out of these had stroke for the first time. Acute ischemic strokes account for almost 87% of all strokes, in which blood flow to the brain is disrupted.
Moreover, surge in the product launches or new approvals is expected to drive the global acute ischemic stroke therapeutics market over the forecast period. For instance, on May 17, 2021, DiaMedica Therapeutics Inc., a biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, recently announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for their biologic therapy drug DM199, which is a recombinant (synthetic) form of human tissue kallikrein-1 (KLK1) and aims to help in improving patient outcomes following acute ischemic stroke and reduce the number of recurrent strokes.
Furthermore, increasing mergers, agreements, and acquisitions by market players are expected to boost the global acute ischemic stroke therapeutics market over the forecast period. For instance, on November 14, 2016, Acticor Biotech SAS and Mediolanum Pharmaceuticals announced a research collaboration agreement for Acticor's project ACT-017, a humanized antibody fragment (Fab). Mediolanum will co-finance the research and development of ACT-017, an antithrombotic treatment for acute ischemic stroke, under the terms of the agreement. These factors are expected to support global acute ischemic stroke therapeutics market growth over the forecast period.
Global Acute Ischemic Stroke Therapeutics Market – Regional Insights
Among regions, North America is expected to dominate the global acute ischemic stroke therapeutics market, owing to the new product releases and approvals. For instance, on November 6, 2020, AstraZeneca, an international biopharmaceutical company focused on the discovery, production and marketing of prescription medicines declared that its drug Brilinta (ticagrelor) has been approved by the U.S. Food and drugs administration (FDA) for the treatment of acute ischemic stroke. Brilinta (ticagrelor) is an oral, reversible, specific P2Y12 receptor antagonist that prevents platelet activation. It can be used to significantly reduce the risk of major adverse cardiovascular (CV) events such as stroke or heart attack, when combined with aspirin.
Furthermore, Asia Pacific region is expected to witness a significant growth in the forecast period, owing to some drug approvals and price cuts on drugs used to treat acute ischemic stroke. For instance, on August 12, 2019, the government of India and the Indian Ministry of Health and Family Welfare included the next-generation drug 'tenecteplase' in new guidelines as a first line treatment to heal the brain clots in acute ischemic stroke patients. Tenecteplase is a thrombolytic drug marketed by Gennova Biopharmaceuticals, a biotechnology company based in Pune focused on developing, producing, and commercializing bio therapeutics. The drug was included as first line treatment in order to reduce treatment costs by nearly half while promoting indigenous research. These factors are expected to support global acute ischemic stroke therapeutics market growth over the forecast period.
Global Acute Ischemic Stroke Therapeutics Market – Taxonomy
By Drug Class:
- Thrombolytic Drugs
- Anti-coagulant Drugs
- Non-steroidal Anti-inflammatory Drugs (NSAID)
- Anti-platelet Drugs
By Route of Administration:
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Global Acute Ischemic Stroke Therapeutics Market – Competitive landscape
Key players operating in the global acute ischemic stroke therapeutics market include DiaMedica Therapeutics Inc, Acticor Biotech SAS, Mediolanum pharmaceuticals S.p.A, Gennova Biopharmaceuticals Ltd., Zocere Inc., Roche Holding AG, Seneca Bophirima Inc., Boehringer Ingelheim, and Athersys Inc.